Navigation Links
WaferGen Reports Second Quarter 2011 Financial Results
Date:9/12/2011

Fee-for-Service.

Net Income/LossThe closing of the $30.6 million financing required a number of new accounting entries for the three and six months ended June 30, 2011 that resulted in non-cash charges to net income totaling $13.2 million, see details below.

For the second quarter ended June 30, 2011, net loss attributable to common stockholders is $18.6 million (of which $13.2 million is non-cash as above), or $(0.45) per share (basic and diluted), compared to a net income attributable to common stockholders of $646,000 or $0.02 per share (basic and diluted), for the same period in 2010. For the six months ended June 30, 2011, WaferGen reported a net loss attributable to common stockholders of $22.5 million (of which $13.2 million is non-cash as above), or $(0.54) per share (basic and diluted), compared to a net loss attributable to common stockholders of $3.9 million, or $(0.12) per share for the same period in 2010.

Of the $13.2 million non-cash charges for the three and six months ended June 30, 2011, $9.3 million is a one-time accretion expense related to a beneficial conversion feature arising on issuance of the Series A-1 convertible preferred stock; $2.3 million is a one-time interest expense arising from the issuance of convertible promissory notes, and $1.6 million is a non-cash expense on the revaluation of the conversion element of the convertible promissory notes, that can fluctuate in future periods based on the company's stock price.

Net loss for the three and six months ended June 30, 2011 was also impacted by warrant derivative revaluations.  Net loss from warrant derivative revaluations for the three months ended June 30, 2011 was $191,000, compared to net gain of $3.6 million for the three months ended June 30, 2010; and net gain of $300,000 for the six months ended June 30, 2011 compared to net gain of $1.7 million for the six months ended June 30, 2010.  These non-cash gains and losses are attributed to r
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. WaferGen to Present at OneMedForum New York 2011
2. WaferGen Closes $30 Million Financing with Three Leading Life Science Institutional Investors
3. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
4. WaferGen Launches High-Throughput SmartChip Human MicroRNA Panel V2
5. WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results
6. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
7. WaferGen to Present at 13th Annual BIO CEO and Investor Conference
8. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
9. WaferGen to Present at OneMedForum San Francisco 2011
10. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
11. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of Jain PharmaBiotech,s new report "Cardiovascular Drug ... offering. , Drug delivery to the ... because of the anatomy and physiology of the vascular ... of the body. Drugs can be introduced into the ...
(Date:3/3/2015)... 2015  Delcath Systems, Inc. (NASDAQ: ... company focused on oncology with an emphasis on ... announces that the results from its Phase 3 ... been submitted for publication in a leading peer-reviewed ... for Injection for use with the Delcath Hepatic ...
(Date:3/3/2015)... Depomed, Inc. (NASDAQ: DEPO ) today ... Annual Roth Conference in Laguna Niguel ... (9:30 am PT) Tuesday, March 10, 2015. The ... via the Investor Relations page of the Depomed website at ... archived for 30 days on the company,s website. ...
Breaking Medicine Technology:Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 2Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 2Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 4Depomed To Present At 27th Annual Roth Conference 2
... control ... with combination therapy -, ... study presents,data demonstrating that patients with Chronic Obstructive Pulmonary ... and symptom control when treated with a,combination of nebulized ...
... Presented at the 2008 International Conference of the American ... ... May 20 Forest Laboratories, Inc. and,Laboratorios Almirall, S.A. today ... of aclidinium bromide, an,investigational treatment for chronic obstructive pulmonary disease ...
Cached Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 2Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 3Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 4Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 5
(Date:3/3/2015)... 2015 The FSH Society , ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), ... . The purpose of the campaign is to spread ... most common forms of muscular dystrophies. , To ... the FSH Society will begin sharing impactful photographs of ...
(Date:3/3/2015)... Presale tickets for Madonna will be ready for purchase ... March 9, with Madonna tour tickets expected to sell out ... talented artist is a significant one for fans, and the ... Ticketability.com to browse the inventory of Madonna tickets at ... enjoy, the 2015 tour is expected to attract attention from ...
(Date:3/3/2015)... 2015 State after state prove ... of probation programs aimed to rehabilitate nonviolent drug ... (tax) cost of incarcerating violators of drug laws, ... alcohol addiction treatment. Governor Bruce Rauner ( R)has ... Illinois' drug and alcohol statewide Department of Alcoholism ...
(Date:3/3/2015)... Using an “intelligent,” rather than random, method ... prescription drug coverage plans could save Medicare and patients ... Pittsburgh Graduate School of Public Health analysis discovered. ... of the journal Health Affairs and build upon an ... than $5 billion in its Part D low-income subsidy ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Volpara Solutions, ... announced that John D. Pavlidis has joined their Board ... of technical and executive management experience in the medical ... large and small organizations. , “John’s broad management experience ... imaging modalities will be a tremendous asset to the ...
Breaking Medicine News(10 mins):Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 2Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 3Health News:Presale Tickets for Madonna: Ticketability.com Announces Madonna Tour Tickets for Sale at Reduced Prices for the Rebel Heart Tour During Presales 2Health News:Gov. of Illinois, Bruce Rauner, Suggests Cutting 25 Million for Drug Rehabilitation, Harbor Village Comments 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 3Health News:Volpara Solutions Adds Medical Imaging Veteran John Pavlidis to Board of Directors 2Health News:Volpara Solutions Adds Medical Imaging Veteran John Pavlidis to Board of Directors 3
... numbers are staggering --,over 20% of people living in ... the impairment or disability which creates dependency and,poverty in ... and political opportunities," says Ron Nabors, Chief,Executive Officer of ... stand up and speak out on the,International Day for ...
... Oct. 16 Children in the South Bay,suffering ... conditions can,now receive specialty care from Lucile Packard ... hospital,s new South Bay,Specialty Center in Los Gatos ... all the hallmarks of its parent institution. ...
... WEST CHESTER, Ohio, Oct. 16 AtriCure, Inc.,(Nasdaq: ... leader in cardiac surgical,ablation products, today announced that ... which physicians have adopted to,treat atrial fibrillation (AF), ... Dr. James H. McClelland, an,electrophysiologist, and colleagues from ...
... the U.S. Food and Drug,Administration,s (FDA,s) Cardiovascular ... majority of members voted to recommend the ... FOSRENOL(R),(lanthanum carbonate), to treat hyperphosphatemia (elevated levels ... disease (CKD) Stage 4 patients.,Currently, FOSRENOL is ...
... and Advertising ... Distribution Agreements, WebMD Announces Third Quarter Earnings ... WebMD Health Corp. (Nasdaq:,WBMD), the leading provider of health information services, ... Preliminary Results for the Three Months Ended September 30, 2007 ...
... Oct. 16 HLTH Corporation,(Nasdaq: HLTH ) today ... months ended September 30, 2007 at approximately 4:00 pm ... previously announced, HLTH Corporation,s 84% owned,subsidiary, WebMD Health Corp. ... their financial results for the three months ended September ...
Cached Medicine News:Health News:CBM USA stands up and speaks out to world leaders on the International Day for the Eradication of Poverty 2Health News:Packard Children's Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home 2Health News:Published Results Using AtriCure Minimally Invasive Products 2Health News:Published Results Using AtriCure Minimally Invasive Products 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 2Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 4Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 5Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 6Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 7Health News:WebMD Reports Preliminary Third Quarter Financial Results 2Health News:WebMD Reports Preliminary Third Quarter Financial Results 3Health News:WebMD Reports Preliminary Third Quarter Financial Results 4Health News:WebMD Reports Preliminary Third Quarter Financial Results 5Health News:WebMD Reports Preliminary Third Quarter Financial Results 6Health News:WebMD Reports Preliminary Third Quarter Financial Results 7Health News:WebMD Reports Preliminary Third Quarter Financial Results 8Health News:WebMD Reports Preliminary Third Quarter Financial Results 9Health News:WebMD Reports Preliminary Third Quarter Financial Results 10Health News:WebMD Reports Preliminary Third Quarter Financial Results 11Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2
The STAAR ELASTIMIDE™ lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
The STAAR ELASTIC LENS®, is a single piece silicone lens to be placed completely in the capsular bag....
Foldable Silicone Multi-piece Lens....
... Lomb UV-Absorbing, Silicone Posterior Chamber Intraocular Lens ... for the visual correction of aphakia in ... in whom the cataractous lens has been ... device is intended to be placed only ...
Medicine Products: